NCT05279768CompletedPhase 1/2
Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.
Potential Use of Umbilical Cord Mesenchymal Stem Cells and Secretoms for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to investigating the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSCs) and secretomes to insulin resistance in Polycystic Ovary Syndrome (PCOS) patients. This study has 4 arms namely UC-MSCs treatment, secretomes treatment, UC-MSCs and secretomes treatment, and control.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 20 Feb 2022
- Start date
- 1 Sept 2022
- Primary completion date
- 20 Jan 2025
- Lead sponsor
- PT. Prodia Stem Cell Indonesia
- NCT number
- NCT05279768
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 44
- From 1 Sept 2022 to the primary completion date, 20 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are not currently on hormon treatment of other resistance treatment.
Other illness
- Patients who are allergic to component of WJ-MSC or Secretome.
- Patients with positive diagnosis of hepatitis A,B,C, and HIV
Other
- Refusing or not participating in part / all of the research process.
Who the study is looking for
- PCOS patients with insulin resistance based on Rotterdam Consensus criteria, i.e. menstrual disorders (oligomenorhea/ amennorhea)
- Patients must have hiperandrogenemia clinical and laboratory proof (Ferriman Gallwey score \>8)
- Patients with Free Androgen Index (FAI) \>4 and ovary polycystic from USG transvaginal
- Patients with Homeostatic (HOMA) IR score ≥ 1.7
Age in the registry: 20 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PT Prodia StemCell Indonesia Coordinator of this site? Confirm its status | Jakarta | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.